Comparison of Two Different Doses of Azithromycin for Treatment of Yaws

Overview

The study will be a single blinded, randomized, controlled open label non-inferiority phase III, trial with two parallel groups, conducted in Ghana and Papua New Guinea (PNG). The ultimate goal is to establish if a 20mg/kg dose of azithromycin is as effective as a 30mg/kg dose in the treatment of yaws. Approximately 600 clinically and serologically diagnosed yaws patients will be included in the study. Patients will be randomized to receive treatment with the two antibiotic regimens as follow: (i) Regimen I (AZT20): Single oral dose of 20 mg/kg azithromycin (ii) Regimen II (AZT30): Single oral dose of 30 mg/kg azithromycin. The follow-up period of patients will be 6 months. Assessments before, during and after the antibiotic treatment will include full medical history, clinical assessment of the lesion and, laboratory investigations. The primary efficacy parameters are healing of the lesion at 4 weeks and a four-fold decline in RPR titre at 6 months after start of treatment.

Full Title of Study: “Randomized Controlled Trial Comparing Efficacy of Single Dose Treatment of Yaws With 20mg/kg Versus 30mg/kg of Azithromycin”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: December 2016

Interventions

  • Drug: Azithromycin
    • Comparison of two different dosing strategies for the treatment of yaws

Arms, Groups and Cohorts

  • Active Comparator: AZT30
    • Single dose of azithromycin at a dose of 30mg/kg – max 2 Grams
  • Experimental: AZT20
    • Single dose of azithromycin at a dose of 20mg/kg – max 1 Grams

Clinical Trial Outcome Measures

Primary Measures

  • Number of Participants With Clinical and Serological Cure
    • Time Frame: 6 Months
    • Clinical resolution of skin lesion at 4 weeks and at least four-fold decline in Rapid Plasma Reagin titre or seroreversion at 6-month (compared to baseline) in T.pallidum subsp. pertenue Polymerase Chain Reaction-confirmed subjects with yaws.

Secondary Measures

  • Number of Participants With Clinical and Serological Cure in Latent Yaws
    • Time Frame: 6 Months
    • Clinical resolution of skin lesion at 4 weeks and at least four-fold decline in Rapid Plasma Reagin titre or seroreversion at 6-month (compared to baseline) in T.pallidum subsp. pertenue Polymerase Chain Reaction-negative.
  • Number of Participants With Adverse Events
    • Time Frame: 6 months
    • To compare the incidences and relative risk of all Adverse Events (AEs), including treatment-related AEs, Serious Adverse Events (SAEs) and grade 3-4 toxicity in patients treated with AZT20 and AZT30 regimens

Participating in This Clinical Trial

Inclusion Criteria

  • Aged 6 to 16 years – Clinical lesion consistent with primary or secondary yaws -Primary ulcer or papilloma – Dually-Positive Chembio DPP Syphilis Screen & Confirm – Informed Consent and Assent (for children 12-16 years) Exclusion Criteria:

1. Known allergy to azithromycin or macrolides. 2. Treatment with long-acting penicillin or alternative antibiotic with activity against T. pallidum within the last 3 months (ceftriaxone, azithromycin or doxycycline, amoxicillin). 3. Patients with current treatment with any drugs likely to interact with the study medication. 4. Patients who are unable to take oral medication or having gastrointestinal disease likely to interfere with drug absorption. 5. Patients who may not be able to comply with the requirements of the study protocol including follow up visits. 6. Patients who are not willing to give informed consent (patient and/or parent/legal representative), or who withdraw consent.

Gender Eligibility: Male

Minimum Age: 6 Years

Maximum Age: 16 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • London School of Hygiene and Tropical Medicine
  • Collaborator
    • World Health Organization
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • David Mabey, Principal Investigator, London School of Hygiene and Tropical Medicine

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.